Genetics Generation Advancement Corp. Stock
Equities
4160
TW0004160007
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
55.3 TWD | +9.94% | +32.30% | +42.16% |
Sales 2022 | 548M 16.81M | Sales 2023 | 592M 18.19M | Capitalization | 988M 30.33M |
---|---|---|---|---|---|
Net income 2022 | 25M 767K | Net income 2023 | 28M 859K | EV / Sales 2022 | 0.75 x |
Net cash position 2022 | 255M 7.83M | Net cash position 2023 | 266M 8.16M | EV / Sales 2023 | 1.22 x |
P/E ratio 2022 |
26.1
x | P/E ratio 2023 |
34.7
x | Employees | 104 |
Yield 2022 |
1.74% | Yield 2023 |
1.31% | Free-Float | 58.95% |
1 day | +9.94% | ||
1 week | +32.30% | ||
Current month | +30.73% | ||
1 month | +29.05% | ||
3 months | +31.98% | ||
6 months | +44.39% | ||
Current year | +42.16% |
Managers | Title | Age | Since |
---|---|---|---|
Cheng Hsien Tsai
CEO | Chief Executive Officer | - | - |
Tai Sheng Chang
CTO | Chief Tech/Sci/R&D Officer | - | - |
Fang Chun Huang
IRC | Investor Relations Contact | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Yue Jen Huang
BRD | Director/Board Member | - | 20-06-09 |
Cheng Hsien Tsai
CEO | Chief Executive Officer | - | - |
Wen Cheng Chang
BRD | Director/Board Member | - | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-25 | 55.3 | +9.94% | 790,476 |
24-04-24 | 50.3 | -0.40% | 1,093,370 |
24-04-23 | 50.5 | +9.90% | 1,218,704 |
24-04-22 | 45.95 | +9.93% | 263,161 |
24-04-19 | 41.8 | 0.00% | 36,174 |
End-of-day quote Taipei Exchange, April 24, 2024
More quotes1st Jan change | Capi. | |
---|---|---|
+42.16% | 43.09M | |
-20.53% | 10.67B | |
+41.94% | 3.22B | |
-36.56% | 2.09B | |
-18.92% | 2.04B | |
-29.19% | 1.46B | |
+15.73% | 1B | |
-4.37% | 734M | |
-37.00% | 391M | |
-46.73% | 379M |
- Stock Market
- Equities
- 4160 Stock